Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns

NCT ID: NCT02997592

Last Updated: 2022-06-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-20

Study Completion Date

2021-08-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns. A prospective, single arm, safety and efficacy, open labeled multi-center study

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SpinCare is an electrospinning portable device intended for the external treatment of burns and wounds. The SpinCare is the first made on the spot, bed side, and completely personalized dressing system; with excellent coverage of all size, shapes and difficult contours. The nano-fibrous dressing mimics the structure of natural body tissue and creates excellent medium for tissue repair and healing.

The objective of this study is to evaluate the performance, safety and efficacy of the SpinCare System in the treatment of superficial to intermediate partial thickness burns.

The study included 3 sites. Adult patients with superficial to intermediate partial thickness burns (second degree superficial to intermediate) of up to 10% TBSA (Total Body Surface Area); with an independent burn of up to 5% TBSA.

A prospective single arm, safety and efficacy, open labeled, multi-center study for the treatment of partial thickness burn wounds not considered for surgery using the SpinCare System.

44 patients enrolled in the study.

Endpoints:

* Wound healing and re-epithelialization on day 21.
* The burn will be considered healed when at least 95% of the total area is re-epithelialized and no scabs exist.

* Ease of use
* At postoperative days 7, 14, 21
* Dermal safety assessed by Draize Score
* Visual estimate of wound healing and re-epithelialization
* Pain
* Infection
* Itching

* Itching and scar quality at 3 and 6 months
* Itching and scar quality at 12 months (optional)
* Device related adverse events

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Partial Thickness Burn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SpinCare

Patients with partial thickness burns treated with the SpinCare System

Group Type EXPERIMENTAL

SpinCare

Intervention Type DEVICE

The burn wound is treated using the SpinCare Systen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SpinCare

The burn wound is treated using the SpinCare Systen

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ≥ 18 years old at enrolment. Both genders.
* The patient has partial thickness burn wounds (second degree superficial to intermediate) of up to 10% TBSA; of which the target wound for treatment is of up to 5% TBSA or up to 300cm2.
* Presenting at the emergency room within the first 24-48 hours post-injury.
* Patient's wound is defined as a partial thickness burn for conservative treatment (superficial to intermediate second degree).
* Patient underwent cleansing/debridement of initial burn before applying the dressing
* The patient is able and willing to comply with study procedures and give written informed consent prior to enrollment in the study

Exclusion Criteria

* Any known or suspected systemic infection
* Any known sensitivity to components/products used in this study
* Any active, uncontrolled, progressive or untreated malignancy
* Use of penicillamine, corticosteroid or immunosuppressive medication within two months prior to enrollment or who is likely to be prescribed these medications or any other medications known to adversely affect wound healing during study participation
* Major uncontrolled systemic disorders such as hepatic, renal, neurologic, or endocrinologic disorders
* Major dermatological disorders such as: psoriasis, pemphigus, Steven Johnson, etc.
* Patients with burns larger than 10% TBSA
* Patients with burns up to 10% TBSA but no target wound of up to 5% TBSA or up to 300cm2
* Patients suffering from electrical or chemical burns.
* Patients suffering from frostbites.
* Patients suffering from burn wounds that are third degree or full thickness.
* Patients suffering from burn wounds in the head, neck or genital areas
* Female patients who are pregnant or nursing
* Psychiatric patient.
* Soldiers
* Participation in another clinical trial within 30 days prior to the Screening Visit
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nanomedic Technologies Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Moti Harats, Dr

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rambam Medical Center

Haifa, , Israel

Site Status

Burn Unit, Sheba Medical Center

Ramat Gan, , Israel

Site Status

Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIP0009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Manuka Honey for Wound Care
NCT02259491 TERMINATED PHASE4
Burn Validation Study
NCT06131203 COMPLETED
CO2 Laser Revision for Burn Related Donor Site Scars
NCT04456127 ACTIVE_NOT_RECRUITING NA